Advertisement
Screener

BIOMARIN PHARMACEUTICAL INC (BMRN) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

BIOMARIN PHARMACEUTICAL INC Selling, General and Administrative Expense

BIOMARIN PHARMACEUTICAL INC (BMRN) reported Selling, General and Administrative Expense of $395.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06

  • BIOMARIN PHARMACEUTICAL INC selling, general and administrative expense for the quarter ending 2026-06-30 was $395.55M, a 70.29% increase year-over-year.
  • BIOMARIN PHARMACEUTICAL INC selling, general and administrative expense for the quarter ending 2026-03-31 was $258.29M, a 25.31% increase year-over-year.
  • BIOMARIN PHARMACEUTICAL INC selling, general and administrative expense for the quarter ending 2025-12-31 was $446.21M, a 67.37% increase year-over-year.
  • BIOMARIN PHARMACEUTICAL INC selling, general and administrative expense for the quarter ending 2025-09-30 was $268.42M, a 5.89% increase year-over-year.
  • BIOMARIN PHARMACEUTICAL INC selling, general and administrative expense for fiscal 2025 was $1.15B, a 14.27% increase from fiscal 2024.
  • BIOMARIN PHARMACEUTICAL INC selling, general and administrative expense for fiscal 2024 was $1.01B, a 13.07% increase from fiscal 2023.
  • BIOMARIN PHARMACEUTICAL INC selling, general and administrative expense for fiscal 2023 was $892.41M, a 8.40% increase from fiscal 2022.
  • BIOMARIN PHARMACEUTICAL INC selling, general and administrative expense for fiscal 2022 was $823.24M, a 8.41% increase from fiscal 2021.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 3 month as first filedSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 6 month as first filedSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 9 month as first filedSelling, General and Administrative Expense 12 monthSelling, General and Administrative Expense 12 month as first filed
2026-06-30$395.55M
10-Q · filed 2026-08-06
$653.84M
10-Q · filed 2026-08-06
$1.10B
derived: sum of 3 quarters · filed 2026-08-06
$1.37B
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$258.29M
10-Q · filed 2026-05-05
$704.50M
derived: sum of 2 quarters · filed 2026-05-05
$972.91M
derived: sum of 3 quarters · filed 2026-05-05
$1.21B
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$446.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$714.62M
derived: sum of 2 quarters · filed 2026-02-26
$946.90M
derived: sum of 3 quarters · filed 2026-08-06
$1.15B
10-K · filed 2026-02-26
2025-09-30$268.42M
10-Q · filed 2025-10-28
$500.69M
derived: sum of 2 quarters · filed 2026-08-06
$706.81M
10-Q · filed 2025-10-28
$973.42M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$232.28M
10-Q · filed 2026-08-06
$438.39M
10-Q · filed 2026-08-06
$705.00M
derived: sum of 3 quarters · filed 2026-08-06
$958.48M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$206.12M
10-Q · filed 2026-05-05
$472.72M
derived: sum of 2 quarters · filed 2026-05-05
$726.20M
derived: sum of 3 quarters · filed 2026-05-05
$989.24M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$266.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$520.09M
derived: sum of 2 quarters · filed 2026-02-26
$783.12M
derived: sum of 3 quarters · filed 2026-02-26
$1.01B
10-K · filed 2026-02-26
2024-09-30$253.48M
10-Q · filed 2025-10-28
$516.51M
derived: sum of 2 quarters · filed 2025-10-28
$742.42M
10-Q · filed 2025-10-28
$1.00B
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$263.03M
10-Q · filed 2025-08-05
$488.94M
10-Q · filed 2025-08-05
$748.45M
derived: sum of 3 quarters · filed 2026-02-26
$964.22M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$225.91M
10-Q · filed 2025-05-02
$485.42M
derived: sum of 2 quarters · filed 2026-02-26
$701.19M
derived: sum of 3 quarters · filed 2026-02-26
$907.29M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$259.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$475.28M
derived: sum of 2 quarters · filed 2026-02-26
$681.38M
derived: sum of 3 quarters · filed 2026-02-26
$892.41M
10-K · filed 2026-02-26
$937.29M
10-K · filed 2024-02-26
2023-09-30$215.77M
10-Q · filed 2024-10-31
$223.93M
10-Q · filed 2023-11-02
$421.87M
derived: sum of 2 quarters · filed 2024-10-31
$632.89M
10-Q · filed 2024-10-31
$662.27M
10-Q · filed 2023-11-02
$847.87M
derived: sum of 4 quarters · filed 2025-02-24
2023-06-30$206.10M
10-Q · filed 2024-08-05
$215.34M
10-Q · filed 2023-08-02
$417.13M
10-Q · filed 2024-08-05
$438.34M
10-Q · filed 2023-08-02
$632.10M
derived: sum of 3 quarters · filed 2025-02-24
$848.91M
derived: sum of 4 quarters · filed 2025-02-24
2023-03-31$211.02M
10-Q · filed 2024-04-26
$223.00M
10-Q · filed 2023-04-28
$426.00M
derived: sum of 2 quarters · filed 2025-02-24
$642.81M
derived: sum of 3 quarters · filed 2025-02-24
$839.65M
derived: sum of 4 quarters · filed 2025-02-24
2022-12-31$214.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24
$431.79M
derived: sum of 2 quarters · filed 2025-02-24
$628.62M
derived: sum of 3 quarters · filed 2025-02-24
$823.24M
10-K · filed 2025-02-24
$854.01M
10-K · filed 2023-02-27
2022-09-30$216.82M
10-Q · filed 2023-11-02
$413.65M
derived: sum of 2 quarters · filed 2023-11-02
$608.27M
10-Q · filed 2023-11-02
$825.83M
derived: sum of 4 quarters · filed 2024-02-26
2022-06-30$196.84M
10-Q · filed 2023-08-02
$391.45M
10-Q · filed 2023-08-02
$609.02M
derived: sum of 3 quarters · filed 2024-02-26
$792.35M
derived: sum of 4 quarters · filed 2024-02-26
2022-03-31$194.62M
10-Q · filed 2023-04-28
$412.18M
derived: sum of 2 quarters · filed 2024-02-26
$595.51M
derived: sum of 3 quarters · filed 2024-02-26
$779.68M
derived: sum of 4 quarters · filed 2024-02-26
2021-12-31$217.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
$400.90M
derived: sum of 2 quarters · filed 2024-02-26
$585.06M
derived: sum of 3 quarters · filed 2024-02-26
$759.38M
10-K · filed 2024-02-26
2021-09-30$183.33M
10-Q · filed 2022-10-28
$367.49M
derived: sum of 2 quarters · filed 2022-10-28
$541.81M
10-Q · filed 2022-10-28
$737.32M
derived: sum of 4 quarters · filed 2023-02-27
2021-06-30$184.16M
10-Q · filed 2022-08-04
$358.48M
10-Q · filed 2022-08-04
$553.99M
derived: sum of 3 quarters · filed 2023-02-27
$733.44M
derived: sum of 4 quarters · filed 2023-02-27
2021-03-31$174.32M
10-Q · filed 2022-04-29
$369.83M
derived: sum of 2 quarters · filed 2023-02-27
$549.28M
derived: sum of 3 quarters · filed 2023-02-27
$724.69M
derived: sum of 4 quarters · filed 2023-02-27
2020-12-31$195.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
$374.96M
derived: sum of 2 quarters · filed 2023-02-27
$550.37M
derived: sum of 3 quarters · filed 2023-02-27
$737.67M
10-K · filed 2023-02-27
2020-09-30$179.45M
10-Q · filed 2021-10-29
$354.86M
derived: sum of 2 quarters · filed 2021-10-29
$542.16M
10-Q · filed 2021-10-29
$730.06M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30$175.41M
10-Q · filed 2021-07-30
$362.71M
10-Q · filed 2021-07-30
$550.61M
derived: sum of 3 quarters · filed 2022-02-25
$720.72M
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31$187.29M
10-Q · filed 2021-04-30
$375.19M
derived: sum of 2 quarters · filed 2022-02-25
$545.31M
derived: sum of 3 quarters · filed 2022-02-25
$706.06M
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31$187.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
$358.01M
derived: sum of 2 quarters · filed 2022-02-25
$518.77M
derived: sum of 3 quarters · filed 2022-02-25
$680.92M
10-K · filed 2022-02-25
2019-09-30$170.11M
10-Q · filed 2020-11-06
$330.87M
derived: sum of 2 quarters · filed 2020-11-06
$493.02M
10-Q · filed 2020-11-06
$657.20M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30$160.75M
10-Q · filed 2020-08-05
$322.91M
10-Q · filed 2020-08-05
$487.08M
derived: sum of 3 quarters · filed 2021-02-26
$635.65M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31$162.16M
10-Q · filed 2020-05-01
$326.33M
derived: sum of 2 quarters · filed 2021-02-26
$474.89M
derived: sum of 3 quarters · filed 2021-02-26
$628.17M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31$164.17M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26
$312.74M
derived: sum of 2 quarters · filed 2021-02-26
$466.02M
derived: sum of 3 quarters · filed 2021-02-26
$604.35M
10-K · filed 2021-02-26
2018-09-30$148.57M
10-Q/A · filed 2019-11-04
$301.85M
derived: sum of 2 quarters · filed 2019-11-04
$440.18M
10-Q/A · filed 2019-11-04
$600.46M
derived: sum of 4 quarters · filed 2020-02-27
2018-06-30$153.28M
10-Q · filed 2019-08-02
$291.62M
10-Q · filed 2019-08-02
$451.90M
derived: sum of 3 quarters · filed 2020-02-27
$582.43M
derived: sum of 4 quarters · filed 2020-02-27
2018-03-31$138.34M
10-Q · filed 2019-04-29
$298.62M
derived: sum of 2 quarters · filed 2020-02-27
$429.15M
derived: sum of 3 quarters · filed 2020-02-27
$572.65M
derived: sum of 4 quarters · filed 2020-02-27
2017-12-31$160.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
$290.81M
derived: sum of 2 quarters · filed 2020-02-27
$434.32M
derived: sum of 3 quarters · filed 2020-02-27
$554.34M
10-K · filed 2020-02-27
2017-09-30$130.53M
10-Q · filed 2018-10-26
$274.04M
derived: sum of 2 quarters · filed 2018-10-26
$394.06M
10-Q · filed 2018-10-26
$537.01M
derived: sum of 4 quarters · filed 2019-02-28
2017-06-30$143.50M
10-Q · filed 2018-08-03
$263.52M
10-Q · filed 2018-08-03
$406.48M
derived: sum of 3 quarters · filed 2019-02-28
$525.24M
derived: sum of 4 quarters · filed 2019-02-28
2017-03-31$120.02M
10-Q · filed 2018-04-27
$262.98M
derived: sum of 2 quarters · filed 2019-02-28
$381.74M
derived: sum of 3 quarters · filed 2019-02-28
$491.31M
derived: sum of 4 quarters · filed 2019-02-28
2016-12-31$142.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28
$261.72M
derived: sum of 2 quarters · filed 2019-02-28
$371.29M
derived: sum of 3 quarters · filed 2019-02-28
$476.59M
10-K · filed 2019-02-28
2016-09-30$118.76M
10-Q · filed 2017-10-31
$228.34M
derived: sum of 2 quarters · filed 2017-10-31
$333.63M
10-Q · filed 2017-10-31
$447.54M
derived: sum of 4 quarters · filed 2018-02-26
2016-06-30$109.58M
10-Q · filed 2017-08-02
$214.88M
10-Q · filed 2017-08-02
$328.78M
derived: sum of 3 quarters · filed 2018-02-26
$422.83M
derived: sum of 4 quarters · filed 2018-02-26
2016-03-31$105.30M
10-Q · filed 2017-05-04
$219.21M
derived: sum of 2 quarters · filed 2018-02-26
$313.25M
derived: sum of 3 quarters · filed 2018-02-26
$414.76M
derived: sum of 4 quarters · filed 2018-02-26
2015-12-31$113.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26
$207.95M
derived: sum of 2 quarters · filed 2018-02-26
$309.46M
derived: sum of 3 quarters · filed 2018-02-26
$402.27M
10-K · filed 2018-02-26
2015-09-30$94.04M
10-Q · filed 2016-11-03
$195.56M
derived: sum of 2 quarters · filed 2016-11-03
$288.36M
10-Q · filed 2016-11-03
$388.13M
derived: sum of 4 quarters · filed 2017-02-27
2015-06-30$101.51M
10-Q · filed 2016-08-08
$194.32M
10-Q · filed 2016-08-08
$294.09M
derived: sum of 3 quarters · filed 2017-02-27
$368.69M
derived: sum of 4 quarters · filed 2017-02-27
2015-03-31$92.81M
10-Q · filed 2016-05-02
$192.57M
derived: sum of 2 quarters · filed 2017-02-27
$267.18M
derived: sum of 3 quarters · filed 2017-02-27
$335.27M
derived: sum of 4 quarters · filed 2017-02-27
2014-12-31$99.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$174.37M
derived: sum of 2 quarters · filed 2017-02-27
$242.46M
derived: sum of 3 quarters · filed 2017-02-27
$302.16M
10-K · filed 2017-02-27
2014-09-30$74.60M
10-Q · filed 2015-11-02
$142.69M
derived: sum of 2 quarters · filed 2015-11-02
$202.39M
10-Q · filed 2015-11-02
$202.52M
10-Q · filed 2014-10-28
$274.57M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$68.09M
10-Q · filed 2015-08-05
$128.16M
10-Q · filed 2015-08-05
$199.97M
derived: sum of 3 quarters · filed 2016-02-29
$261.81M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31$60.07M
10-Q · filed 2015-05-05
$131.88M
derived: sum of 2 quarters · filed 2016-02-29
$193.72M
derived: sum of 3 quarters · filed 2016-02-29
$244.38M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$71.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$133.65M
derived: sum of 2 quarters · filed 2016-02-29
$184.31M
derived: sum of 3 quarters · filed 2016-02-29
$235.36M
10-K · filed 2016-02-29
2013-09-30$61.84M
10-Q · filed 2014-10-28
$112.50M
derived: sum of 2 quarters · filed 2014-10-28
$163.55M
10-Q · filed 2014-10-28
$218.60M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30$50.66M
10-Q · filed 2014-07-31
$101.71M
10-Q · filed 2014-07-31
$156.75M
derived: sum of 3 quarters · filed 2015-03-02
$203.09M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31$51.05M
10-Q · filed 2014-05-02
$106.10M
derived: sum of 2 quarters · filed 2015-03-02
$152.44M
derived: sum of 3 quarters · filed 2015-03-02
$203.97M
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31$55.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
$101.39M
derived: sum of 2 quarters · filed 2015-03-02
$152.93M
derived: sum of 3 quarters · filed 2015-03-02
$198.17M
10-K · filed 2015-03-02
2012-09-30$46.34M
10-Q · filed 2013-10-28
$97.88M
derived: sum of 2 quarters · filed 2013-10-28
$143.12M
10-Q · filed 2013-10-28
$191.58M
derived: sum of 4 quarters · filed 2014-02-26
2012-06-30$51.54M
10-Q · filed 2013-07-29
$96.79M
10-Q · filed 2013-07-29
$145.24M
derived: sum of 3 quarters · filed 2014-02-26
$190.12M
derived: sum of 4 quarters · filed 2014-02-26
2012-03-31$45.25M
10-Q · filed 2013-04-29
$93.70M
derived: sum of 2 quarters · filed 2014-02-26
$138.58M
derived: sum of 3 quarters · filed 2014-02-26
$179.60M
derived: sum of 4 quarters · filed 2014-02-26
2011-12-31$48.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26
$93.33M
derived: sum of 2 quarters · filed 2014-02-26
$134.35M
derived: sum of 3 quarters · filed 2014-02-26
$175.42M
10-K · filed 2014-02-26
2011-09-30$44.88M
10-Q · filed 2012-10-29
$85.89M
derived: sum of 2 quarters · filed 2012-10-29
$126.97M
10-Q · filed 2012-10-29
$169.03M
derived: sum of 4 quarters · filed 2013-02-26
2011-06-30$41.02M
10-Q · filed 2012-08-02
$82.09M
10-Q · filed 2012-08-02
$124.15M
derived: sum of 3 quarters · filed 2013-02-26
$162.50M
derived: sum of 4 quarters · filed 2013-02-26
2011-03-31$41.04M
10-Q · filed 2012-04-30
$83.14M
derived: sum of 2 quarters · filed 2013-02-26
$121.48M
derived: sum of 3 quarters · filed 2013-02-26
$158.76M
derived: sum of 4 quarters · filed 2013-02-26
2010-12-31$42.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
$80.45M
derived: sum of 2 quarters · filed 2013-02-26
$117.72M
derived: sum of 3 quarters · filed 2013-02-26
$151.72M
10-K · filed 2013-02-26
2010-09-30$38.35M
10-Q · filed 2011-10-31
$75.63M
derived: sum of 2 quarters · filed 2011-10-31
$109.63M
10-Q · filed 2011-10-31
$146.15M
derived: sum of 4 quarters · filed 2012-02-22
2010-06-30$37.28M
10-Q · filed 2011-08-01
$71.28M
10-Q · filed 2011-08-01
$107.81M
derived: sum of 3 quarters · filed 2012-02-22
$136.47M
derived: sum of 4 quarters · filed 2012-02-22
2010-03-31$34.00M
10-Q · filed 2011-04-29
$70.53M
derived: sum of 2 quarters · filed 2012-02-22
$99.19M
derived: sum of 3 quarters · filed 2012-02-22
$129.72M
derived: sum of 4 quarters · filed 2012-02-22
2009-12-31$36.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22
$65.19M
derived: sum of 2 quarters · filed 2012-02-22
$95.72M
derived: sum of 3 quarters · filed 2012-02-22
$124.29M
10-K · filed 2012-02-22
2009-09-30$28.67M
10-Q · filed 2010-10-29
$59.19M
derived: sum of 2 quarters · filed 2010-10-29
$87.76M
10-Q · filed 2010-10-29
2009-06-30$30.53M
10-Q · filed 2010-08-04
$59.09M
10-Q · filed 2010-08-04
2008-12-31$106.57M
10-K · filed 2011-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05